[ Price : $8.95]
Bausch + Lomb recalls all enVista intraocular lenses due to increasing adverse event reports of toxic anterior segment syndrome as...[ Price : $8.95]
Axsome Therapeutics says its solriamfetol missed the primary endpoint in a Phase 3 proof-of-concept trial to treat major depressiv...[ Price : $8.95]
Compass Therapeutics reports statistically significant top-line data on the primary efficacy endpoint from its COMPANION-002 trial...[ Price : $8.95]
FDA releases the form FDA-483 with three observations from an inspection at the Pompano Beach, FL-based SKNV outsourcing facility.[ Price : $8.95]
FDA warns Jacksonville, FL-based Next Science that it is illegally manufacturing and distributing adulterated and misbranded medic...[ Price : $8.95]
HHS begins terminating FDA employees, with many receiving email notifications in the early morning hours or being denied entrance ...[ Price : $8.95]
FDA accepts for priority review an Apellis Pharmaceuticals supplemental NDA for Empaveli (pegcetacoplan) for treating two severe a...[ Price : $8.95]
Despite HHS secretary Robert F. Kennedy, Jr.s promises to boost transparency at HHS and its health agencies, staff cuts now occurr...